uni-leipzig-open-access/json/s00432-022-04220-w

{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T05:24:10Z","timestamp":1705641850834},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Advances in therapy of metastatic castration-refractory prostate cancer (mCRPC) resulted in more therapeutic options and led to a higher need of predictive\/prognostic biomarkers. Systemic inflammatory biomarkers could provide the basis for personalized treatment selection. This study aimed to assess the modified Glasgow Prognostic Score (mGPS), the neutrophile-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammation index (SII) in men with mCRPC under docetaxel.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with mCRPC and taxane chemotherapy at a tertiary care centre between 2010 and 2019 were screened retrospectively. The biomarkers mGPS, NLR, PLR and SII were assessed and analyzed for biochemical\/radiologic response and survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 118 patients. Of these, 73 (61.9%) had received docetaxel as first-line, 31 (26.2%) as second-line and 14 (11.9%) as third-line treatment. For biochemical response, mGPS (odds ratio (OR) 0.54, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) and PLR (OR 0.63, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) were independent predictors in multivariable analysis. SII was significant in first-line cohort only (OR 0.29, <jats:italic>p<\/jats:italic>\u2009=\u20090.02). No inflammatory marker was predictive for radiologic response. In multivariable analysis, mGPS and NLR (hazard ratio (HR) 1.71 and 1.12, both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) showed significant association with OS in total cohort and mGPS in the first-line cohort (HR 2.23, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Haemoglobin (Hb) and alkaline phosphatase (AP) showed several significant associations regarding 1\u00a0year, 3\u00a0year, OS and biochemical\/radiologic response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pre-treatment mGPS seems a promising prognostic biomarker. A combination of mGPS, NLR and further routine markers (e.g., Hb and AP) could yield optimized stratification for treatment selection. Further prospective and multicentric assessment is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04220-w","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:03:36Z","timestamp":1659945816000},"page":"3371-3381","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort"],"prefix":"10.1007","volume":"149","author":[{"given":"Manuel","family":"Neuberger","sequence":"first","affiliation":[]},{"given":"Nora","family":"Goly","sequence":"additional","affiliation":[]},{"given":"Janina","family":"Skladny","sequence":"additional","affiliation":[]},{"given":"Veronica","family":"Milczynski","sequence":"additional","affiliation":[]},{"given":"Christel","family":"Wei\u00df","sequence":"additional","affiliation":[]},{"given":"Frederik","family":"Wessels","sequence":"additional","affiliation":[]},{"given":"Katja","family":"Nitschke","sequence":"additional","affiliation":[]},{"given":"Britta","family":"Gr\u00fcne","sequence":"additional","affiliation":[]},{"given":"Cael\u00e1n M.","family":"Haney","sequence":"additional","affiliation":[]},{"given":"Friedrich","family":"Hartung","sequence":"additional","affiliation":[]},{"given":"Jonas","family":"Herrmann","sequence":"additional","affiliation":[]},{"given":"Jonas","family":"Jarczyk","sequence":"additional","affiliation":[]},{"given":"Karl F.","family":"Kowalewski","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Waldbillig","sequence":"additional","affiliation":[]},{"given":"Maximilian C.","family":"Kriegmair","sequence":"additional","affiliation":[]},{"given":"Niklas","family":"Westhoff","sequence":"additional","affiliation":[]},{"given":"Thomas S.","family":"Worst","sequence":"additional","affiliation":[]},{"given":"Philipp","family":"Nuhn","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"4220_CR1","unstructured":"Cancer Stat Facts: Prostate Cancer. Retrieved 06.11.2021, from https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"4","key":"4220_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3390\/cancers13040773","volume":"13","author":"K Ando","year":"2021","unstructured":"Ando K, Sakamoto S, Saito S, Maimaiti M, Imamura Y, Sazuka T, Sato N, Komiya A, Anzai N, Ichikawa T (2021) Prognostic value of high-sensitivity modified Glasgow prognostic score in castration-resistant prostate cancer patients who received docetaxel. Cancers 13(4):773","journal-title":"Cancers"},{"issue":"1","key":"4220_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","volume":"16","author":"AJ Armstrong","year":"2010","unstructured":"Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16(1):203\u2013211","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4220_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvi\u00e8re O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263\u2013282","journal-title":"Eur Urol"},{"key":"4220_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","volume":"132","author":"RD Dolan","year":"2018","unstructured":"Dolan RD, Laird BJA, Horgan PG, McMillan DC (2018) The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit Rev Oncol Hematol 132:130\u2013137","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"4220_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.acuro.2020.08.001","volume":"44","author":"MJ Donate-Moreno","year":"2020","unstructured":"Donate-Moreno MJ, Lorenzo-S\u00e1nchez MV, D\u00edaz I, de Mera-S\u00e1nchez ML, Esper-Rueda HRJA, Legido-G\u00f3mez O, Rico-Marco S, Salinas-S\u00e1nchez AS (2020) Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer. Actas Urol Esp 44(10):692\u2013700","journal-title":"Actas Urol Esp"},{"key":"4220_CR7","first-page":"1","volume":"5","author":"DL Draeger","year":"2021","unstructured":"Draeger DL, Groh S, Buchholz T, Woehl M, Nolting J, Hakenberg OW (2021) Prediction of treatment response and survival with chemotherapy for metastatic penile cancer by the modified Glasgow prognostic score. Urol Int 5:1\u20137","journal-title":"Urol Int"},{"issue":"4","key":"4220_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/pros.23465","volume":"78","author":"L Fan","year":"2018","unstructured":"Fan L, Wang R, Chi C, Cai W, Zhang Y, Qian H, Shao X, Wang Y, Xu F, Pan J, Zhu Y, Shangguan X, Zhou L, Dong B, Xue W (2018) Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate 78(4):250\u2013256","journal-title":"Prostate"},{"issue":"3","key":"4220_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100118","volume":"6","author":"G Fornarini","year":"2021","unstructured":"Fornarini G, Rebuzzi SE, Banna GL, Calabr\u00f2 F, Scandurra G, De Giorgi U, Masini C, Baldessari C, Naglieri E, Caserta C, Manacorda S, Maruzzo M, Milella M, Buttigliero C, Tambaro R, Ermacora P, Morelli F, Nol\u00e8 F, Astolfi C, Sternberg CN (2021) Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open 6(3):100118","journal-title":"ESMO Open"},{"issue":"9","key":"4220_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048324","volume":"11","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Xu D, Song H, Qiu B, Tian D, Li Z, Ji Y, Wang J (2021) Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis. BMJ Open 11(9):e048324","journal-title":"BMJ Open"},{"issue":"7","key":"4220_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236445","volume":"15","author":"MR Kim","year":"2020","unstructured":"Kim MR, Kim AS, Choi HI, Jung JH, Park JY, Ko HJ (2020) Inflammatory markers for predicting overall survival in gastric cancer patients: a systematic review and meta-analysis. PLoS ONE 15(7):e0236445","journal-title":"PLoS ONE"},{"issue":"2","key":"4220_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s41669-020-00219-6","volume":"5","author":"K Kreis","year":"2021","unstructured":"Kreis K, Horenkamp-Sonntag D, Schneider U, Zeidler J, Glaeske G, Weissbach L (2021) Treatment-related healthcare costs of metastatic castration-resistant prostate cancer in germany: a claims data study. Pharmacoecon Open 5(2):299\u2013310","journal-title":"Pharmacoecon Open"},{"issue":"11","key":"4220_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4111\/kju.2015.56.11.749","volume":"56","author":"SM Lee","year":"2015","unstructured":"Lee SM, Russell A, Hellawell G (2015) Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma. Korean J Urol 56(11):749\u2013755","journal-title":"Korean J Urol"},{"issue":"4","key":"4220_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clgc.2013.04.020","volume":"11","author":"A Linton","year":"2013","unstructured":"Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G (2013) Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 11(4):423\u2013430","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"4220_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JU.0000000000001376","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS (2021) Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART II. J Urol 205(1):22\u201329","journal-title":"J Urol"},{"issue":"1","key":"4220_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11764-021-01006-w","volume":"16","author":"T Michaeli","year":"2022","unstructured":"Michaeli T, Michaeli D (2022) Prostate cancer follow-up costs in Germany from 2000 to 2015. J Cancer Surviv 16(1):86\u201394","journal-title":"J Cancer Surviv"},{"issue":"17","key":"4220_CR17","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1002\/cam4.4143","volume":"10","author":"M Naszai","year":"2021","unstructured":"Naszai M, Kurjan A, Maughan TS (2021) The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: a systematic review and meta-analysis. Cancer Med 10(17):5983\u20135997","journal-title":"Cancer Med"},{"issue":"2","key":"4220_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","volume":"79","author":"A Neeb","year":"2021","unstructured":"Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, Athie A, Casals T, Carmichael J, Rodrigues DN, Gurel B, Rescigno P, Rekowski J, Welti J, Riisnaes R, Gil V, Ning J, Wagner V, Casanova-Salas I, Cordoba S, Castro N, Fenor de la Maza MD, Seed G, Chandran K, Ferreira A, Figueiredo I, Bertan C, Bianchini D, Aversa C, Paschalis A, Gonzalez M, Morales-Barrera R, Suarez C, Carles J, Swain A, Sharp A, Gil J, Serra V, Lord C, Carreira S, Mateo J, de Bono JS (2021) Advanced prostate cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol 79(2):200\u2013211","journal-title":"Eur Urol"},{"issue":"4","key":"4220_CR19","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.21873\/anticanres.15668","volume":"42","author":"M Neuberger","year":"2022","unstructured":"Neuberger M, Skladny J, Goly N, Wessels F, Wei\u00df C, Egen L, Erben P, Gr\u00fcne GRWMB, Hartung F, Herrmann J, Honeck P, Jarczyk J, Kowalewski KF, M\u00fchlbauer J, Nitschke K, Nientiedt M, Walach MT, Waldbillig F, Westhoff N, Kriegmair VONHJM, Worst TS, Nuhn P (2022) Baseline modified Glasgow prognostic score predicts radiologic response and overall survival in metastatic hormone sensitive prostate cancer treated with docetaxel chemotherapy. Anticancer Res 42(4):1911\u20131918","journal-title":"Anticancer Res"},{"key":"4220_CR20","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D. K., AWMF) 2021 \"Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, diagnose und therapie der verschiedenen stadien des Prostatakarzinoms, Langversion 6.2, Oktober 2021, AWMF Registernummer: 043\/022OL.\" from http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/ (Access date: 20.03.2022)."},{"issue":"19","key":"4220_CR21","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.1002\/cam4.4205","volume":"10","author":"J Pan","year":"2021","unstructured":"Pan J, Wang J, Wei Y, Zhang T, Zhang S, Ye D, Zhu Y (2021) Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: a post hoc analysis of two randomized trials. Cancer Med 10(19):6697\u20136704","journal-title":"Cancer Med"},{"key":"4220_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12935-019-0785-2","volume":"19","author":"H Peng","year":"2019","unstructured":"Peng H, Luo X (2019) Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis. Cancer Cell Int 19:70","journal-title":"Cancer Cell Int"},{"issue":"2","key":"4220_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/pcan.2011.60","volume":"15","author":"K Shafique","year":"2012","unstructured":"Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS (2012) Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow inflammation outcome study. Prostate Cancer Prostatic Dis 15(2):195\u2013201","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4220_CR24","doi-asserted-by":"publisher","first-page":"3456629","DOI":"10.1155\/2021\/3456629","volume":"2021","author":"X Song","year":"2021","unstructured":"Song X, Zhang H, Yin F, Guo P, Yang X, Liu J, Han Y, Ren Z (2021) Systemic inflammatory markers for predicting overall survival in patients with osteosarcoma: a systematic review and meta-analysis. Mediators Inflamm 2021:3456629","journal-title":"Mediators Inflamm"},{"issue":"5","key":"4220_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clgc.2019.06.012","volume":"17","author":"J Stangl-Kremser","year":"2019","unstructured":"Stangl-Kremser J, Lemberger U, Hassler MR, Bruchbacher A, Ilijazi D, Garstka N, Kramer G, Haitel A, Abufaraj M, Shariat SF (2019) Prevalence and prognostic value of the polymorphic variant 1245A>C of HSD3B1 in castration-resistant prostate cancer. Clin Genitourin Cancer 17(5):389\u2013394","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"4220_CR26","doi-asserted-by":"publisher","first-page":"600.e609","DOI":"10.1016\/j.urolonc.2019.11.005","volume":"38","author":"J Stangl-Kremser","year":"2020","unstructured":"Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D\u2019Andrea D, Korn SM, Pones M, Kramer G, Karakiewicz P, Enikeev DV, Glybochko PV, Briganti A, Shariat SF (2020) Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol 38(6):600.e609-600.e615","journal-title":"Urol Oncol"},{"issue":"3","key":"4220_CR27","first-page":"1302","volume":"25","author":"Q Wang","year":"2021","unstructured":"Wang Q, Zhu SR, Huang XP, Liu XQ, Liu JB, Tian G (2021) Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. Eur Rev Med Pharmacol Sci 25(3):1302\u20131310","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"4220_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pros.23969","volume":"80","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, Nakamura K, Komiya A, Nakatsu H, Ichikawa T (2020) Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate 80(7):559\u2013569","journal-title":"Prostate"},{"issue":"1","key":"4220_CR29","doi-asserted-by":"publisher","first-page":"12.e13","DOI":"10.1016\/j.urolonc.2021.08.001","volume":"40","author":"X Zhou","year":"2022","unstructured":"Zhou X, Fu G, Zu X, Xu Z, Li HT, D\u2019Souza A, Tulpule V, Quinn DI, Bhowmick NA, Weisenberger DJ, Liang G, Chen J (2022) Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urol Oncol 40(1):12.e13-12.e22","journal-title":"Urol Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04220-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04220-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04220-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:08:43Z","timestamp":1688213323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04220-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4220"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00432-022-04220-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":["Cancer Research","Oncology","General Medicine"],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study has been conducted according to the Declaration of Helsinki; all patients gave their written informed consent. This study was approved by the local ethics committee (University of Heidelberg\u2019s Ethics Committee II, Medical Faculty Mannheim, reference number 2015-549\u00a0N-MA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}